APWA
KRBP

Atlas Private Wealth Advisors’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Atlas Private Wealth Advisors’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-67
Closed -$17K – 922
2020
Q4 		$17K Buy
+67
New +$19K 0.01% 360

Other funds holding KRBP

1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atlas Private Wealth Advisors's KRBP Position: Q1 2021 in Review

Atlas Private Wealth Advisors sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q1 2021, closing a stake of 67 shares — an estimated $17K sold.

Atlas Private Wealth Advisors first reported a position in KRBP in Q4 2020 and held it in 1 quarter. The position peaked at $17K in Q4 2020. 11 funds tracked by Wall St. Rank hold KRBP as of Q1 2021.

  • Atlas Private Wealth Advisors reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Atlas Private Wealth Advisors sold 67 Kiromic BioPharma, Inc. Common Stock shares in Q1 2021, an estimated $17K.
  • Atlas Private Wealth Advisors first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Atlas Private Wealth Advisors's Kiromic BioPharma, Inc. Common Stock position peaked at $17K in Q4 2020.
  • 11 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q1 2021.

Based on Atlas Private Wealth Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.